# Enzalutamide in Patients With High-risk Prostate Cancer

> **NCT01927627** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT01927627
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-11
- **Primary completion:** 2017-03-29
- **Final completion:** 2017-04-26
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927627, "Enzalutamide in Patients With High-risk Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01927627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*